Search bioRxiv⌕ Search

Biology subjects

Kornilov, S. A.

Publications and source records attributed to Kornilov, S. A..

3 recordsLinked to original sources

Omitted familial extrinsic risk inflates inferred intrinsic lifespan heritability

Shenhar et al. (2026) report 50% "intrinsic" lifespan heritability after calibrating a one-component correlated-frailty survival model to Scandinavian twin lifespans. Their framework is mathematically coherent, but the intrinsic component is not identified if heritable, mortality-relevant extrinsic susceptibility is omitted at calibration. We show that one-component calibration absorbs omitted familial extrinsic structure into the intrinsic frailty scale parameter{sigma}{theta} , and that this variance absorption is visible through separate diagnostics (1) Variance absorption. Under misspecification,{sigma}{theta} is inflated by +22.1% (95% CI: 21.5-22.7%), corresponding to +49% inflation in [Formula]. Falconer h2 is downstream of calibration and inherits a +9.2 pp bias (95% CI: 8.7-9.7). The{sigma}{theta} inflation is model-general: +22% (GM), +18% (MGG), +14% (SR); any dependence summary that is strictly increasing in{sigma}{theta} inherits this inflation, so Falconer h2 is one affected downstream quantity among many (Corollary B3). (2) Structural fingerprint. In the joint twin survival surface S(t1, t2), misspecification produces systematic dependence errors (ISE 48x that of the recovery model). Conditional twin dependence is inflated at all ages, peaking at age 80 ({Delta}r = 0.048). (3) Specificity. The bias requires an omitted component that is both heritable and mortality-relevant. Three negative controls, a boundary check ({rho} = 0), and a two-component recovery refit ({sigma}{theta} restored to within -3.2%) establish specificity. ACE decomposition yields C {approx} 0 throughout: the omitted extrinsic component loads onto A (because it is shared 1.0/0.5 in MZ/DZ), so switching summary statistics does not restore identification. (4) Sensitivity and falsifiability. Over an empirically anchored regime ({sigma}{gamma} [isin] [0.30, 0.65],{rho} [isin] [0.20, 0.50]), Falconer bias ranges from +2.8 to +18.9 pp (mean 9 pp). If{rho} is sufficiently negative, the bias reverses sign in all three model families (Corollary B4). A full-likelihood robustness check shows that this upward pull is partly structural and partly estimator-specific: in the same misspecified one-component model, ML still inflates{sigma}{theta} (+3%), whereas matching only rMZ inflates it much more (+21%). These results do not resolve true intrinsic heritability but establish that Shenhars 50% estimate carries a structured, model-general upward bias originating in the fitted latent variance{sigma}{theta} .

genetics↗

Novel Oral LNAD+ Increases Intracellular NAD and Metabolic Flux Without Elevating Circulating NAD: Evidence from a Randomized Controlled Trial

Declines in nicotinamide adenine dinucleotide (NAD+) are linked to metabolic stress accompanying aging and disease. While precursor-based approaches elevate systemic NAD, their clinical translation can be constrained by biosynthetic bottlenecks and first-pass metabolism. RENEWAL-NAD+ (ClinicalTrials.gov NCT07336836; retrospectively registered 01/04/2026) was a double-blind, randomized, placebo-controlled Phase 0/1b trial in healthy adults aged 45-75 years (60 randomized; primary analysis n=50) evaluating 5 days of oral LathMized(R) NAD+ (LNAD+), a physicochemically modulated formulation that alters the supramolecular organization and solution behavior of NAD+ while preserving its native molecular structure. The primary endpoints were change in intracellular NAD (icNAD), measured in whole blood, and circulating NAD (cirNAD), measured in separated plasma, relative to baseline. LNAD+ produced a rapid and pronounced increase in icNAD, with a 53% elevation versus placebo at Day 6 (p=5.48e-14; Hedges g=3.66), while cirNAD was unchanged (p=0.60), demonstrating compartment-selective augmentation. Plasma NAD catabolites increased substantially (1-methyl-nicotinamide, MeNAM p=5.39e-13; N1-methyl-2-pyridone-5-carboxamide, 2PY p=2.95e-16), consistent with downstream engagement of NAD metabolic flux. Exploratory analyses identified non-overlapping correlates for the two compartments (cirNAD tracking inflammatory and metabolic markers, icNAD tracking red blood cell indices and NAM). Treatment was very well tolerated: symptom incidence was comparable between groups (p=0.68), only one mild adverse event (nausea, Grade 1) occurred in the LNAD+ arm, and no secondary clinical, vital-sign, wellbeing, or wearable-derived endpoint survived multiplicity correction. These data demonstrate rapid intracellular NAD augmentation after oral LNAD+ dosing with pharmacodynamic evidence of downstream metabolism, compartment-specific physiological signatures, and a favorable short-term safety profile, with exploratory multi-omic analyses ongoing.

systems biology↗

Manifestations of genetic risk for Alzheimer's Disease in the blood: a cross-sectional multi-omic analysis in healthy adults aged 18-90+

Deeply phenotyped cohort data can elucidate differences associated with genetic risk for common complex diseases across an age spectrum. Previous work has identified genetic variants associated with Alzheimers disease (AD) risk from large-scale genome-wide association study meta-analyses. To explore effects of known AD-risk variants, we performed a phenome-wide association study on ~2000 clinical, proteomic, and metabolic blood-based analytes obtained from 2,831 cognitively normal adult clients of a consumer-based scientific wellness company. Results uncovered statistically significant SNP-analyte associations for five genetic variants after correction for multiple testing (for SNPs in or near NYAP1, ABCA7, INPP5D, and APOE). These effects were detectable from early adulthood. Sex modified the effects of four genetic variants, with multiple interrelated immune-modulating effects associated with the PICALM variant. Sex-stratified GWAS results from an independent AD case-control meta-analysis supported sexspecific disease effects of the PICALM variant, highlighting the importance of sex as a biological variable. These analyses support evidence from previous functional genomics studies in the identification of a causal variant within the PILRA gene. Taken together, this study highlights clues to the earliest effects of AD genetic risk variants in individuals where disease symptoms have not (yet) arisen.

genetics↗